Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 29:36:11729.
doi: 10.3389/ti.2023.11729. eCollection 2023.

Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement

M Carbone  1   2 , A Della Penna  3 , C Mazzarelli  4 , E De Martin  5 , C Villard  2   6 , A Bergquist  6 , P D Line  7   8   9 , J M Neuberger  10 , S Al-Shakhshir  11 , P J Trivedi  11 , U Baumann  12 , L Cristoferi  1   2 , J Hov  7   8   9 , B Fischler  13   14 , N H Hadzic  15 , D Debray  16 , L D'Antiga  17 , N Selzner  18 , L S Belli  4 , S Nadalin  3
Affiliations

Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement

M Carbone et al. Transpl Int. .

Abstract

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.

Keywords: IBD; PSC; immunosuppression; liver transplantation; retransplantation.

PubMed Disclaimer

Conflict of interest statement

MC has received grant support unrelated to this study from Genetics spa, PSC Pediatric Foundation, AMAF, EpaC and AIRCS. He also received speakers/consultancy/advisory fees for GlaxoSmithKline, Dr. Falk Pharma, Cymabay, Advanz Pharma, Albireo, Ipsen, Mayoly Spindler, Perspectum, Echosens, Kowa, and Mirun. PT receives institutional support from Birmingham NIHR BRC. Unrelated to this study PT has received grant support from the Wellcome Trust, Innovate UK, the Medical Research Foundation, GlaxoSmithKline (GSK), Guts UK, PSC Support, LifeArc, NIHR, Intercept Pharma, Dr. Falk Pharma, Gilead Sciences, and Bristol Myers Squibb. He has also received speaker fees from Intercept and Dr. Falk, and advisory board/consultancy fees from Intercept, Cymabay, Pliant Pharma, Dr. Falk, Albireo, Ipsen and GlaxoSmithKine. HNH consultancies for Arrowhead, Takeda, GLG, Albireo, Alnylam and Mirum. LC received speakers fee from Advanz and Echosens. LD’A received consultancy fees from: Albireo, Mirum, Alexion, Astra Zeneca, Selecta, Vivet, Spark, Genespire, and Tome, in fields unrelated to the current topic. DD received consultancy fees from: Mirum, Vertex, Orphalan, Univar, Alexion, in fields unrelated to this study. UB received consultancy fees or grant support from: Mirum, Albireo, Alexion, Nestle and Vivet in fields unrelated to this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. European Association for the Study of the Liver. Electronic Address: easloffice@easloffice.eu; European Association for the Study of the LiverEuropean Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol (2022) 77(3):761–806. 10.1016/j.jhep.2022.05.011 - DOI - PubMed
    1. Andersen IM, Fosby B, Boberg KM, Clausen OP, Jebsen P, Melum E, et al. Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway. Transpl Direct (2015) 1(9):e39. 10.1097/TXD.0000000000000548 - DOI - PMC - PubMed
    1. Liaskou E, Quraishi MN, Trivedi PJ. Mucosal Immunity in Primary Sclerosing Cholangitis: From the Bowel to Bile Ducts and Back Again. Curr Opin Gastroenterol (2022) 38(2):104–13. 10.1097/MOG.0000000000000809 - DOI - PubMed
    1. Hov JR, Karlsen TH. The Microbiota and the Gut-Liver Axis in Primary Sclerosing Cholangitis. Nat Rev Gastroenterol Hepatol (2023) 20(3):135–54. 10.1038/s41575-022-00690-y - DOI - PubMed
    1. Cillo U, Weissenbacher A, Pengel L, Jochmans I, Roppolo D, Amarelli C, et al. ESOT Consensus Platform for Organ Transplantation: Setting the Stage for a Rigorous, Regularly Updated Development Process. Transpl Int (2022) 35:10915. 10.3389/ti.2022.10915 - DOI - PMC - PubMed

MeSH terms

Substances

Grants and funding

All costs related to taskforce and workgroup meetings were covered by ESOT, without external funding.
-